ALK Inhibitor Response in Melanomas Expressing EML4-ALK sorted by
relevance

Admin03.09.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

37010
Admin25.09.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

5700
Admin08.10.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

Admin12.09.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

7701
Admin27.07.2021

(PDF) ALK inhibitor response in melanomas expressing EML4

1700
Admin18.07.2021

ALK Inhibitor Response in Melanomas Expressing EML4-ALK

2108
Admin22.08.2021

Effects of ALK inhibition in the EML4-ALK-positive NSCLC

Admin09.10.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

7308
Admin03.09.2021

Combined inhibition of ALK and MEK enhances response and

8805
Admin16.07.2021

The ALK mutation L1152R causes the ALK tyrosine kinase

4509
Admin09.10.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

6704
Admin17.09.2021

The combination of ALK and PLX4032 inhibitors is efficient

9005
Admin29.08.2021

Combined inhibition of ALK and MEK enhances response and

8900
Admin29.08.2021

ALK inhibitor sensitivity of EML4-ALK variants. A, Ba/F3

3306
Admin09.10.2021

ALK inhibitor sensitivity and protein stability of KIF5b

6909
Admin04.09.2021

Cancers | Free Full-Text | Mechanisms of Acquired

9801
Admin20.07.2021

FDA approved ALK inhibitors with substantial impact in the

Admin10.09.2021

ATCC - The Generation of an EML4-ALK Fusion NSCLC Isogenic

3805
Admin13.07.2021

EML4-ALK (E13;A20, variant 1) lung adenocarcinoma cells

6105
Admin02.08.2021

Intracellular distribution of EML4-ALK variants and

15010
Admin27.09.2021

Frontiers | A Systemic Review of Resistance Mechanisms and

604